# Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke

Study · id `cardio:ct-nct07423975` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07423975](<https://clinicaltrials.gov/study/NCT07423975>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07423975

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 159 participants.

## Technical summary

Registry record NCT07423975. Randomized; single masking; primary purpose treatment. Start 2026-04-08 (actual); primary completion 2026-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 159 participants (planned count; ClinicalTrials.gov record NCT07423975, source copy `cardio:ctgov-nct07423975-2026-10-16`, retrieved 2026-10-26)
- Started: 2026-04-08 (actual) (ClinicalTrials.gov record NCT07423975, source copy `cardio:ctgov-nct07423975-2026-10-16`, retrieved 2026-10-26)
- Primary completion: 2026-10-30 (anticipated) (ClinicalTrials.gov record NCT07423975, source copy `cardio:ctgov-nct07423975-2026-10-16`, retrieved 2026-10-26)
- Completion: 2027-01-30 (anticipated) (ClinicalTrials.gov record NCT07423975, source copy `cardio:ctgov-nct07423975-2026-10-16`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07423975, source copy `cardio:ctgov-nct07423975-2026-10-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07423975-2026-10-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Advancing Reperfusion Therapy for Ischemic Stroke: Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke
- Acronym: ARTS-SAFE
- Condition: Stroke Acute
- Condition: Endovascular Treatment
- Intervention (Drug): High-dose Anakinra
- Intervention (Drug): Low-dose Anakinra
- Intervention (Other): Standard medical treatment
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

## Provenance

Content hash: 915d915aec460c2b8bae1e2fed2209651bc3cf5bd588335459d346b39919bf63
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
